XML 38 R27.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Intangible Assets and Royalty Agreement (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets Activity Summary | Intangible assets are summarized as follows (in thousands):
| Weighted Average Amortization Lives |  | September 30, 2016 |  | December 31, 2015
|  |  | Cost |  | Cost
Licenses (a) (b) (c) (d) | 7 years |  | $ | 1,699 |  |  | $ | 1,009 |
Patents & Know How (b) (d) | 19 years |  | 17,211 |  |  | 8,001 |
Customer & Supplier Relationships (b) (d) | 13 years |  | 9,851 |  |  | 3,761 |
Tradenames & Trademarks (b) (d) | indefinite |  | 1,838 |  |  | 1,008 |
Non-compete agreements (d) | 4 years |  | 1,080 |  |  | — |
In Process Research & Development (b) | n/a |  | 25 |  |  | 25 |
Patents in Process (c) | n/a |  | 2,298 |  |  | 1,823 |
Total |  |  | 34,002 |  |  | 15,627 |
Less Accumulated amortization and impairment charges |  |  | (6,753 | ) |  | (4,864 | )
Net |  |  | $ | 27,249 |  |  | $ | 10,763 |
(a) | On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.
(b) | On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the nine months ended September 30, 2016, approximately $40,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.
(c) | Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.
(d) | On January 13, 2016, the Company acquired Stability. As a result, the Company recorded intangible assets for Patents & Know - How of $9,170,000, Customer Relationships of $6,090,000, Non - compete agreements of $1,080,000, Tradenames & Trademarks of $830,000 and Licenses of $690,000.
Estimated Future Amortization Expense for Intangible Assets | Expected future amortization of intangible assets as of September 30, 2016, is as follows (in thousands):
Year ending December 31, | Estimated Amortization Expense
2016 (a) | $ | 630 |
2017 | 2,430 |
2018 | 2,075 |
2019 | 2,075 |
2020 | 1,805 |
Thereafter | 16,396 |
| $ | 25,411 |
(a) Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after September 30, 2016.

X
- Definition Tabular disclosure of intangible assets activity, which may be broken down by segment or major class. + References No definition available. + Details
Name: | mdxg_ScheduleOfIntangibleAssetsActivityTableTextBlock
Namespace Prefix: | mdxg_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration